Abstract
Background
Ethnicity
is
known
to
be
an
important
correlate
of
health
outcomes,
particularly
during
the
COVID-19
pandemic,
where
some
ethnic
groups
were
shown
at
higher
risk
infection
and
adverse
outcomes.
The
recording
patients’
in
primary
care
can
support
research
efforts
achieve
equity
service
provision
outcomes;
however,
coding
ethnicity
present
complex
challenges.
We
therefore
set
out
describe
detail
with
a
view
supporting
use
this
data
wide
range
settings,
as
part
wider
robustly
define
methods
using
administrative
data.
Methods
completeness
consistency
OpenSAFELY-TPP
database,
containing
linked
hospital
records
>
25
million
patients
England.
also
compared
breakdown
that
2021
UK
census.
Results
78.2%
registered
on
1
January
2022
had
their
recorded
records,
rising
92.5%
when
supplemented
was
for
women
than
men.
rate
ranged
from
77%
South
East
England
82.2%
West
Midlands.
rates
chronic
or
other
serious
conditions.
For
each
five
broad
groups,
within
2.9
percentage
points
population
Census
whole.
multiple
98.7%
latest
ethnicities
matched
most
frequently
coded
ethnicity.
Patients
whose
categorised
Other
likely
have
discordant
(32.2%).
Conclusions
Primary
OpenSAFELY
over
three
quarters
all
patients,
combined
sources
high
level
completeness.
overall
distribution
across
English
practices
similar
Census,
regional
variation.
This
report
identifies
best
available
codelist
electronic
record
Journal of Travel Medicine,
Год журнала:
2023,
Номер
30(7)
Опубликована: Июнь 19, 2023
Infectious
disease
epidemiology
is
continuously
shifting.
While
travel
has
been
disrupted
by
the
COVID-19
pandemic
and
travel-related
epidemiological
research
experienced
a
pause,
further
shifts
in
vaccine-preventable
diseases
(VPDs)
relevant
for
travellers
have
occurred.
PLoS ONE,
Год журнала:
2024,
Номер
19(3), С. e0294897 - e0294897
Опубликована: Март 21, 2024
Background
SARS-CoV-2
variant
Omicron
rapidly
evolved
over
2022,
causing
three
waves
of
infection
due
to
sub-variants
BA.1,
BA.2
and
BA.4/5.
We
sought
characterise
symptoms
viral
loads
the
course
COVID-19
with
these
in
otherwise-healthy,
vaccinated,
non-hospitalised
adults,
compared
data
infections
preceding
Delta
concern
(VOC).
Methods
In
a
prospective,
observational
cohort
study,
healthy
vaccinated
UK
adults
who
reported
positive
polymerase
chain
reaction
(PCR)
or
lateral
flow
test,
self-swabbed
on
alternate
weekdays
until
day
10.
participant-reported
load
trajectories
between
caused
by
VOCs
(sub-variants
BA.4/5),
tested
for
relationships
vaccine
dose,
PCR
cycle
threshold
(Ct)
as
proxy
using
Chi-squared
(χ2)
Wilcoxon
tests.
Results
563
episodes
were
among
491
participants.
Across
episodes,
there
was
little
variation
symptom
burden
(4
[IQR
3–5]
symptoms)
duration
(8
6–11]
days).
Whilst
profiles
differed
sub-variants,
similar
sub-variants.
Anosmia
more
frequently
after
2
doses
sub-variant
3
doses,
example:
42%
(25/60)
participants
9%
(6/67)
BA.4/5
(χ
P
<
0.001;
OR
7.3
[95%
CI
2.7–19.4]).
Fever
less
common
(20/60
participants;
33%)
than
(39/67;
58%;
χ
=
0.008;
0.4
[CI
0.2–0.7]).
Amongst
an
coryza,
fatigue,
cough
myalgia
predominated.
Viral
peaks
did
not
differ
Delta,
Omicron,
irrespective
severity
(including
asymptomatic
participants),
VOC
vaccination
status.
Ct
values
negatively
associated
time
since
infected
BA.1
(β
-0.05
(CI
-0.10–0.01);
0.031);
however,
this
trend
observed
infections.
Conclusion
Our
study
emphasises
both
changing
profile
era,
ongoing
transmission
risk
adults.
Trial
registration
NCT04750356
.
The Lancet Regional Health - Europe,
Год журнала:
2023,
Номер
30, С. 100636 - 100636
Опубликована: Май 3, 2023
Kidney
disease
is
a
key
risk
factor
for
COVID-19-related
mortality
and
suboptimal
vaccine
response.
Optimising
vaccination
strategies
essential
to
reduce
the
burden
in
this
vulnerable
population.
We
therefore
compared
effectiveness
of
two-
three-dose
schedules
involving
AZD1222
(AZ;
ChAdOx1-S)
BNT162b2
(BNT)
among
people
with
kidney
England.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 7, 2025
Abstract
We
investigated
and
compared
mortality
rates
risk
factors
for
pre-pandemic
pandemic
all-cause
in
a
population-based
cohort
of
men
women
Arkhangelsk,
Russia.
A
prospective
study
enrolled
2,324
participants
aged
35
to
69
years
between
2015
2017.
All
were
followed
up
deaths
using
the
registry.
Mortality
per
1000
person-years
calculated
periods.
Cox
regression
models
used
investigate
demographic,
lifestyle,
health
characteristics
associated
with
increased
death
both
During
pandemic,
age-standardized
women,
but
minor
change
was
observed
men.
Older
age,
smoking,
diabetes
higher
periods
sexes.
In
during
obesity,
angina,
elevated
cystatin
C
levels,
history
COVID-19.
men,
asthma
hs-Troponin
T
levels
while
hs-CRP
NT-proBNP
Targeted
preventive
interventions
specific
can
be
implemented
potential
future
infectious
disease
outbreaks.
Journal of Inflammation Research,
Год журнала:
2025,
Номер
Volume 18, С. 3385 - 3397
Опубликована: Март 1, 2025
Purpose:
Immunocompromised
patients
are
at
increased
risk
for
severe
outcomes
from
COVID-19
due
to
their
altered
immune
responses,
yet
inflammatory
profiles
and
the
interplay
between
immunosuppression
remain
poorly
understood.
We
aimed
illustrate
inflammation
profile
clinical
of
hospitalized
immunocompromised
with
COVID-19.
Methods:
conducted
a
retrospective
study
using
multicenter
database
included
adult
Corona
virus
disease
2019
(COVID-19)
in
China's
late
2022
wave.
Crude
adjusted
28-
60-day
mortality
was
compared
two
groups.
Inflammatory
phenotypes
were
evaluated
by
serum
interleukin-6
(IL-6)
C-reactive
protein
(CRP)
level.
The
overt
analyzed.
Results:
Among
4078
patients,
348
(8.5%)
immunocompromised.
had
lower
crude
but
higher
28-day
(hazard
ratio
[HR]
=
1.55;
95%
CI
1.08
2.23)
(HR
1.47;
1.05
2.06).
Besides,
developing
hyperinflammation
(odd
[OR]
=1.92;
1.47
2.50,
p
<
0.001).
Moreover,
mediated
major
part
deleterious
survival
effect
on
Conclusion:
Immunodeficiency
not
only
increases
short-term
also
predisposes
hyperinflammation.
complex
immunosuppression,
hyperinflammation,
warrants
more
detailed
profiling
immunity
this
population.
Keywords:
COVID-19,
in-hospital
mortality,
